Senior Med Affairs Professional/ Formerly GSK, SVP Global Medical Affairs
Danie is a senior pharmaceutical executive with 25 years’ experience mainly in medical affairs. He has a passion for modernising medical affairs and track record in leadership, people development, capability building and coaching. Danie is a qualified MD with a Masters in Clinical Pharmacology who combines medical and life science qualifications with an MBA. Danie has extensive experience building international teams, driving change and working in regulated markets for GlaxoSmithKline (GSK) across Europe, the Americas, Middle East, Africa, Australasia and Japan.He previously worked for Eli Lilly & Company for 17 years in different medical roles as well as marketing and sales. During his different roles, he was based in South Africa, United Kingdom and Australia. Before joining the Pharmaceutical Industry, Danie had his own primary care practice. Danie started his own mentoring, coaching and consulting business, TheNextVersion Ltd, in Jul 2018.
The Medical Futurist, and Director of The Medical Futurist Institute
Dr. Bertalan Mesko, PhD is The Medical Futurist and the Director of The Medical Futurist Institute analyzing how science fiction technologies can become reality in medicine and healthcare. As a geek physician with a PhD in genomics, he is also an Amazon Top 100 author. He is also a Private Professor at Semmelweis Medical School, Budapest, Hungary.
With 500+ presentations including courses at Harvard, Stanford and Yale Universities, Singularity University’s Futuremed course at NASA Ames campus and organizations including the 10 biggest pharmaceutical companies, he is one of the top voices globally on healthcare technology.
Dr. Mesko was featured by dozens of top publications, including CNN, the World Health Organization, National Geographic, Forbes, TIME magazine, BBC, and the New York Times. He publishes his analyses regularly on medicalfuturist.com.
IFAPP Academy Vice President & International Affairs, IFAPP (International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine)
President, Brazilian Association of Pharmaceutical Medicine
Dr. Kesselring received his medical degree from University of São Paulo, Brazil and pursued further postgraduate training in Gynecology , Obstetrics and Mastology. He also received postgraduate qualifications in Clinical Pharmacology, Drug Development and Regulation at the Tufts Institute for Professional Development, USA.
For the past three decades Gustavo has been intimately involved in clinical research for both the public and private sector in Brazil as well as internationally . He was Director of Clinical Research for several multinational pharmaceutical companies in his country. He was appointed Director of the National Clinical Research Training Program for the Ministry of Health in Brazil while serving at the same time as Director of Clinical Research at the Science Institute, German Hospital Oswaldo Cruz, São Paulo.
From 2010 until 2015 he was Executive Director Latin America of the ViS Research Institute, which optimizes drug development by enabling access to a complete map of global clinical research infrastructure. ViS is current part of IMS Health.
Gustavo served as advisor for the World Medical Association for the revision of the Declaration of Helsinki (versions 2008 & 2013). He received awards by the American Academy of Clinical Research Professionals in 2011 and by the Drug Information Association in 2013 in recognition for his contributions to global clinical research and pharmaceutical medicine.
Dr. Kesselring is also the current President of the Brazilian Society of Pharmaceutical Medicine and serves in the board of other nonprofit organizations. He has published several articles on clinical research and medicines development and has been speaker and chairperson at international conferences in USA, Europe, Latin America and Asia.
Having successfully pioneered the adoption of Customer Experience Management to address challenges commonly faced in these sectors, Mike became the first pharma company executive globally to be awarded CCXP status by the Customer Experience Professionals Association (CXPA). Helping organisations to stop just talking about the development of customer value and enabling them to consistently deliver it through day-to-day operations is a challenge he loves to work on.
Transforming the commercial functions of a large pharmaceutical companies across Europe, integrating new customer focused management practices to deliver an improved customer experience
Evolved launch and business planning processes across multiple organisations to adopt customer experience management concepts and methods
Led cultural change initiatives across multiple countries and cultures to develop customer / patient first mind-sets and behaviours
Established customer feedback mechanisms and metrics across multiple key markets; developing associated governance models that use the data developed to drive leadership decision making
Launched and managed large and small pharmaceutical products across multiple territories in Europe
First pharma executive globally to be awarded CCXP status
Michael Calopietro has leadership experience in the commercial, non-profit and academic sectors. He has 6 years of experience in the health care and pharmaceutical industries – where he has focused on bringing innovation into continuing medical education and professional development programmes. Prior to joining Novo Nordisk, he spent 12 years as a management consultant at PriceWaterhouseCoopers, where he specialised in streamlining customer experiences for Fortune 500 companies. Michael has Masters Degree in Global Health and has worked in Europe, Africa and North America.
Medical Head European Markets, Australia & Canada, Bristol-Myers Squibb
Dr Faisal Mehmud joined BMS in July 2016 initially to lead the UK and Ireland Medical organisation and is now Head of the European Medical group.
He has held a variety of senior leadership roles, most recently at Novartis in the USA, where he was the Vice President of US Clinical Development and Medical Affairs Oncology. Previously he was at GSK, where he was Head of the USA North American Medical Affairs/Clinical Development group for Oncology & Haematology and prior to this he held several roles of increasing seniority at GSK in the UK and at Sanofi in the UK and Paris, France (corporate).
Dr Mehmud has extensive experience in late phase drug development, interaction with regulators, HTA bodies and academic co-operative groups globally over 15 years in a variety of therapeutic areas.
Dr Mehmud graduated in Medicine from Cambridge University, and before his time in industry, was a practicing physician in the UK in general medicine and oncology.
Jan van Overbeeke, M.Sc., MBA, based in Tokyo, co-leads Medical Affairs for McKinsey across Asia. As part of his work, he provides leadership in client service on medical topics across the Asia region, publishes in the public domain, oversees McKinsey’s Medical Affairs Performance Evaluation Survey and hosts Medical Affairs leadership round-tables. Mr. van Overbeeke started with McKinsey in the Netherlands, and since then has served pharmaceutical and medical device companies across Europe, the US and Asia during his 3 year tenure in the United Kingdom and since 2014 in Japan. A native of the Netherlands, Mr. van Overbeeke received his Engineering degree from the Technical University of Delft and his law degree from the University of Leiden. He completed a full-time MBA program at INSEAD in Singapore and France.
Isma Benattia, MD, MBA, currently serves as the Head of Medical for the European headquarters and affiliate Medical teams, across all therapeutic areas. Dr Benattia is very passionate about patient involvement in the Research & Development of innovative medicines, the life-cycle management of marketed products and is working extensively with various stakeholders to involve patients in the benefit-risk assessment of medicines.
Prior to her current role, Dr Benattia was responsible for advancing Amgen’s leadership in Global Patient Safety & Labelling. With over 20 years of industry experience, she has held various roles with increasing level of responsibility in different organizations. Prior to joining Amgen, she served as Vice President and Head of Safety Surveillance and Risk Management at Sanofi Genzyme. She has also worked in Clinical Development, Marketing, Medical Affairs and Executive Management at Eli Lilly France, Pfizer, and Wyeth Pharmaceuticals.
Dr Benattia received her medical degree from Faculte de Medecine d’Alger and Faculte de Medecine Pitie Salpetriere Paris, specializing in Psychiatry with a focus on the pharmacology of psychotropics. She also earned Master of Business Administration at the Massachusetts Institute of Technology Sloan School of Management, as well as Master in Bioethics from the University of Pennsylvania.
Merinke was born on the 25th of March 1974 in the south of the Netherlands, within cycling distance of Eindhoven, where she attended the Eckart College.
In 1992 she got admitted to Medical school at Maastricht University. In 1998 she obtained her Medicine Masters Degree, after finishing an internship in Zimbabwe at the department of internal Medicine. In 2005 she completed her specialisation in family Medicine and started working as a GP in a combined pharmacy/GP practice. She has been specialising in travel Medicine and Palliative care.
Nowadays she is GP and part-owner of 3 GP practices in the south of the Netherlands.
Merinke is married and has two children. Merinke has been diagnosed with an auto-immune vasculitis, dd EGPA in 2015.
Since 2019 she is an active volunteer in the Dutch vasculitis foundation.
(MAPS President) / EVP and Head of Medical Affairs / Astellas Pharma
Charlotte M. E. Kremer, MD, MBA is the Executive VP and head of Medical Affairs for Astellas. In this role, Dr. Kremer provides leadership for the Medical Affairs organization globally.
Dr. Kremer joined Astellas in 2012 with 20 years of experience in the pharmaceutical industry. Prior to Astellas, she held the position of Vice President, Therapeutic Area Head for Ophthalmology, PVD, Rare Diseases and Neuroscience at Pfizer. While at Pfizer, she successfully led and executed the clinical development and global medical programs in these respective areas. Prior to joining Pfizer, Dr. Kremer held positions of increasing responsibility providing medical support, developing Phase 3b/4 clinical trials, and initiating and directing a Medical Liaison program at Organon Pharmaceuticals, both in the Netherlands and in the United States. A native of the Netherlands, Dr. Kremer received her medical degree from the University of Utrecht, The Netherlands. She went on to receive her Diploma Pharmaceutical Medicine (DPM) from Universite Libre de Bruxelles. After transferring to the United States, Dr. Kremer completed the Executive MBA program at New York University’s Leonard N. Stern School of Business.
Vice President, Global Medical Affairs Services / Ipsen Pharma SA
Dr Mónica de Abadal is an Executive Leadership Committee Member of the Medical Affairs Professional Society EMEA with more than 16 years of experience in the pharmaceutical industry
Dr de Abadal has experience in multiple therapeutic areas, including oncology, endocrinology and movement disorders as well as operational and strategic Medical Affairs experience in diverse disciplines of medical affairs and product commercialization, such as leading compliance and SOP/policy efforts, quality management systems, data generation, field-based medical teams (MSLs), safety, medical communication & publications
She has served as a board member in companies specialized in telemedicine and has international Medical Affairs experience in Europe, APAC (Australia) and global positions, including deputy Chief Medical Officer, Global Head of Publications. She currently holds the VP Global Medical Affairs Services group position at Ipsen.
Dr de Abadal obtained her medical degree from the University of Barcelona and entered residency in Anaesthesiology in Hospital Vall d´Hebron (Barcelona) ). She validated her medical degree in the US (USMLE) and obtained an MBA specialized in Healthcare administration from (USF) and a postgraduate diploma in Pharmaceutical Medicine (UAB).
She feels passionate about Medical Excellence.
Senior Director, Global Medical Affairs / AstraZeneca
Dr. Ogün Sazova has graduated Istanbul University Faculty of Medicine and has a specialization degree for family medicine. After spending 5 years in clinical and research setting, he joined pharmaceutical industry in 2003 and worked in local medical and commercial roles before joining AstraZeneca (AZ) Turkey as the Head of Primary Care Medical Affairs. In this role, Ogün has built the MSL function in AZ Turkey amongst other medical affairs deliverables.
In 2009, Ogün moved to EU regional organization in Brussels and was the EU Medical Affairs Director for Cardiovascular Diseases. In 2012, he was appointed as the Global Nominated Signatory Practice Director in Global Medical Excellence group, and moved to London with his family. In this role, Ogün has set standards for Nominated Signatory operations worldwide, including risk & control framework, training, accreditation, and many examples of simplification. After this role, Ogün has taken over the lead of the Global Medical Academy and established it as one of the important tools in AZ to drive world-class scientific engagements by medical teams in the countries.
After working in Turkey, Germany and Belgium, Ogün now lives in the UK and works as the Enterprise External Scientific Engagement Lead in AZ Global Medical Affairs.
Lori Mouser is the Global Head of Medical Customer Engagement at F. Hoffman La Roche. She champions the success of MSLs to advance medicine through their engagements with healthcare providers. Leading MSL teams for over 17 years, Lori brings the experience from a range of therapeutic areas. She has US and Global exposure and operates with a commitment to creating solutions through collaboration.
Lori’s first MSL position was at Aventis (now Sanofi) where she quickly gravitated to leading MSL teams during her 12 years with the company. Joining the Roche organization at Genentech in 2012, Lori ultimately had responsibility for the national US Oncology MSL and field leadership teams. Building upon that background, Lori expanded her scope in 2017 to serve the Roche global organization in her current role.
Lori holds a Doctor of Pharmacy Degree and prior to the pharmaceutical industry, she had an
academic career as an Associate Professor in Clinical Pharmacy at Washington State University.
VP, Global Head of Scientific Engagement Strategy, Operations and Program Management / Sanofi
Meg Heim as VP, Global Head of Scientific Engagement Strategy, Operations and Program Management, is a key member of the Primary Care (PC) Business Unit at Sanofi. Meg’s role participates as a member of various Global teams and committees to further strengthen and globalize the Diabetes, Cardiovascular and Established Products.
Meg is responsible for crafting and executing the integrated North America PC Medical Scientific Communications strategy. She is responsible to define, manage and lead the activities that include publications strategy, home and field medical communications and Outcomes Liaison Scientific Exchange with our Payer Customers for North America.
Meg has held officer roles and Executive Global Medical, Sales and Marketing positions with a number of healthcare, medical device and health information technology companies.
Meg is a Registered Nurse with a master’s in administrative science, with Post Masters certificates in Non-Profit Organizational Development and Global Leadership from Fairleigh Dickinson University.
Global Medical Lead – Orphan Diseases / Vifor Pharma
Peter Rutherford is Global Medical Lead for Renal Rare Disease at Vifor Pharma in Zurich, CH. He qualified in Medicine at the University of Newcastle upon Tyne, UK and completed postgraduate medical training to obtain MRCP in 1989. He entered an academic training pathway in Nephrology with an MRC Training Fellowship allowing him to complete a PhD in cell physiology as well as completing clinical training in Nephrology and Internal Medicine. He was then an MRC Travelling Fellow at Yale University School of Medicine gaining additional academic experience in molecular biology.
After return to the UK as Lecturer in Medicine at the Unversity of Newcastle, he was appointed as Senior Lecturer in Nephrology at the University of Wales College of Medicine and Consultant Nephrologist. In this role, he combined clinical practice in delivering a full range of nephrology services with academic work. Peter then developed expertise as a clinical leader in the hospital and became the Medical Director of a combined acute, community and mental health NHS organization leading on patient safety, clinical effectiveness, service improvement and research. In addition he was a Clinical advisor at NICE and chaired their Guidelines Review Panel until he joined Pharma in 2007.
From 2007 to 2015 he was Medical Director Renal for Europe, Middle East and Africa at Baxter Healthcare – being responsible for all aspects of Medical Affairs activities across the region. He worked on research projects in patient support, decision making and education as well as new product development for home dialysis. From 2015 to 2017 he was Head of Integrated Market Access at Quintiles in Europe and Emerging Markets – supporting small and large Pharma and emerging biotech companies with medical affairs, medical communications, market access and patient centric services. Focused on launch brands, Peter support a range of companies across a range of therapeutic areas. Since joining Vifor Pharma, he is back on home ground in Nephrology but working in systemic diseases affecting every organ system.
Chief Medical Officer & EVP, Development and Medical Practices, UCB
Prof. Dr. med. Iris Loew-Friedrich is Chief Medical Officer for UCB, a member of the company’s Executive Committee and Head of the Development & Medical Practices. She provides strategic global leadership for world-wide clinical development, medical affairs, regulatory affairs, real world evidence, patient safety/pharmacovigilance and external engagement. Iris started her service for patients in the pharmaceutical industry in 1992 with a focus on clinical development in the areas of immunology, bone disease and neurology, delivering together with her teams several novel medicines to patients. She held various positions in Research and Development in different companies, always with a focus on global drug development. Since 2001, prior to joining UCB, Iris was the Global Head of Research and Development at Schwarz Pharma (acquired by UCB in 2006) and a member of their Executive Committee. Iris is a physician, board-certified in internal medicine, with a medical license from the University of Frankfurt where she also holds a visiting professorship at the Medical School. Iris is active in industry associations, a member of different supervisory boards, including the board of TransCelerate and PhRMA Foundation. She is passionate about making a difference to the lives of people living with severe diseases.
VP, Medical Affairs - International Developed Markets, Regional Medical Lead / Pfizer
Damian Largier is a South African born physician who completed a Masters in Obstetrics and Gynecology at the University of Cape Town with a focus on Developmental Endocrinology. After five years in clinical practice he joined the pharmaceutical industry initially with Glaxo Wellcome and then as Country Medical Director for Pfizer in South Africa. He has held leadership positions for Pfizer Medical Affairs in Europe and the United States as well as at a Global level with a particular focus on medical communications and late stage product development. He is now the Vice President Medical Affairs for the International Developed Markets (Europe, Japan and Developed Asia) for Internal Medicine.
Alexandra Safronova, MD is currently Medical Director and Head of Medical Affairs at Boehringer-Ingelheim, Russia.
Dr. Safronova earned her medical degree from Moscow Medical Academy cum laude. She completed her residency in internal medicine at Moscow Medical Academy, and fellowships in intensive care at Pirogov Medical University and endocrinology at the Russian Medical Postgraduate Academy.
Before her pharmaceutical career, Dr. Safronova served as a staff physician in the Cardiology and Intensive Care Department at Medical Center of the Russian Academy of Science.
Dr. Safronova started her career in the pharmaceutical industry in 1999 as Clinical Research Scientist at GlaxoSmithKline, then she worked as Manager of Clinical Operations at Quintiles (now IQVIA).
In 2010 she joined Teva as Director of Clinical Research. Her primary task there was to set up Clinical Research Department from the scratch to support registration of new products and supervise global studies. Within two years Teva became #1 in clinical research in Russia. The company received 7 new market authorizations supported by the results of clinical program developed and executed by the department headed by Dr. Safronova. In 2013 Dr Safonova focused on building Medical Affairs function as Medical Director of Russia and CIS, Teva Pharmaceutical.
Dr. Safronova’s experience in multiple therapeutic areas includes Phases I-IV and diverse disciplines of medical affairs and product commercialization, such as leading office based and field-based medical teams (MSLs), PV/safety, Regulatory Affairs, Medical information, Patient Advocacy.
Director of Strategic Partnering, Medical Operations & Executive Board Secretary of Medical Affairs Forum / Novo Nordisk
Kasper Tarp Mortensen is an experienced business director, with a Masters Degree in Finance & Strategy, and additional executive education from Harvard Business School, INSEAD, and IMD. He has 12 years of broad functional and geographic pharma experience, and has spent the last 7 years in Medical Affairs in Novo Nordisk. He now heads the Strategic Partnering area, that maintain partnerships with internal and external stakeholders to ensure strategic alignment on global scientific activities. In his work, Kasper closely collaborates with key Novo Nordisk markets across the world, and has lived in Africa, South America, North America, Europe and Asia.
Chief Medical Officer, SVP Head of Global Medical Affairs OBG / Eisai
Dr. Kirk Shepard is the 2016-2017 President of the Medical Affairs Professional Society and has more than 25 years of experience in the pharmaceutical industry. He is a board-certified medical oncologist and hematologist physician. He is currently Senior Vice President, Head of Global Medical Affairs Oncology at Eisai Pharmaceutical Company.
Dr. Shepard’s experience in multiple therapeutic areas includes operational and strategic product development from Phases I through IV and the diverse disciplines of medical affairs and product commercialization, such as leading compliance and SOP/policy efforts, health economics & outcomes research & patient access, data generation, field-based medical teams (MSLs), PV/safety, medical communication & publications, patient advocacy, and public relations. In 2015, he was selected as one of the 100 Most Inspiring People in the Pharmaceutical Industry (PharmaVOICE).
Before his pharmaceutical career, Dr. Shepard served as a staff physician in the Department of Hematology and Medical Oncology at the Cleveland Clinic Foundation, where he supervised numerous studies in oncology and symptom control. He has more than 50 medical publications in journals and books. Dr. Shepard earned his bachelor’s degree from Cornell University in Ithaca, NY, and his medical degree from the University of Cincinnati Medical School in Cincinnati, OH. He completed both his internship and residency in internal medicine at Case Western Reserve University in Cleveland, OH, and fellowships in hematology and oncology at the University of Chicago Hospitals and Clinics in Chicago, IL.
Vice President, Global Head of Medical Strategy and Innovation/ Allergan
Kevin is a UK qualified pharmacist with nearly 15 years experience in medical affairs internationally. He has grown his career within medical affairs from an MSL role within the UK to building an International team of 200. Kevin worked on the integration and building of a new Medical department following the acquisition of Allergan by Actavis and on the separation of a Medical department following the divestiture of the Allergan generics business to Teva. Most recently Kevin has been working on bold proposals to reshape how Medical Affairs will adapt to the changing healthcare and consumer markets as peoples’ expectations rapidly evolve.
Senior Director, Insights and Training Global Lead, Medical Communications, Medical Affairs/ Astellas
Milana Zivkov is a Senior Director, Insights & Training Global Lead, Medical Affairs, Astellas, located in Northbrook, IL, USA. She has been with Astellas since 2013 in various roles of increasing responsibility within Scientific Publications in Medical Affairs. She was instrumental in establishing Scientific Publications as a strategic partner across M & D, and from 01 July 2018, in new her new role, she is responsible for setting up Insights & Training function within Astellas. She has MD and MSc (Clinical Pharmacology) degrees from University of Belgrade Medical School, and is a fully trained neuropsychiatrist. Following a career in clinical psychiatry, Milana has worked in the pharmaceutical industry for more than 20 years holding positions in various Medical Affairs.
Dr. João Dias is an honors graduate of the University of Helsinki. He received his Licentiate/MSc in biochemistry from the Universities of Porto, Portugal and Wageningen, the Netherlands; and his PhD studies in Immuno-Oncology and Gene Therapy at Helsinki University Central Hospital and Helsinki University, faculty of Medicine.
He is currently responsible for international medical affairs and clinical development for the medical devices and diagnostics portfolio at Haemonetics which includes Hemostasis Management, Cell Salvage and Transfusion Management products. Prior to this role, João had a variety of roles of increasing responsibility in the areas of both market access and medical marketing.
He has authored several peer-reviewed publications and white papers in the fields of Hemostasis, Patient Blood Management, Immuno-Oncology, Gene Therapy, Hematology, and Molecular Biology.
Prior to his tenure at Haemonetics, João worked as a scientist in the development of new products in Cancer Gene Therapy and served as a Life Sciences Consultant working together with multiple global life-science companies.”
Principal/Consultant, Medical Innovation and Insights, and Fmr. VP, Global Medical Excellence, AstraZeneca
Mary Alice Dwyer, PharmD, is an experienced Medical Affairs leader with expertise and proven track record in creating transformational change initiatives, building and leading effective Medical Affairs teams, and implementing patient-centric practices. An enterprise-wide and global leader whose achievements include developing and leading a Medical Excellence function that elevated Medical Affairs deliverables through global, regional, and local medical partnerships while ensuring strong governance processes. Mary Alice has led patient centricity practices, which have established patient networks that provide insight and impact drug development.
Most recently, Mary Alice was Vice President of Global Medical Excellence (GME) at AstraZeneca. She led the GME organization which included Global Publications, Global MSL Excellence, Global Nominated Signatory, the Medical Academy, Medical Resources, and Patient Centricity (PaCe). In this role, she led the partnership between GME and Medical in the regions and countries to build and sustain medical capabilities, skills and knowledge. Mary Alice first joined AstraZeneca in 2004 as the Executive Director of Scientific Affairs and was subsequently promoted to Vice President of Medical Affairs in the US. She has also led scientific and medical teams at Takeda, Pharmacia, and Searle. She previously worked in clinical drug development at Hoffmann-LaRoche and Glaxo.
Mary Alice is currently the Principal/Consultant with Medical Innovation and Insights, providing Medical Affairs consulting services.
Executive Assistant to Corporate VP of Global Medical Affairs/ Novo Nordisk
Teresa Sophie Kemmerich has 7 years of experience in the pharmaceutical industry, most recently as Executive Assistant to the Corporate Vice President in Medical Affairs (Novo Nordisk A/S). Teresa drives strategic, cross-functional projects in close collaboration with senior stakeholders across the organization, with a particular focus on scientific business development. She is part of the global Medical Affairs leadership team in Novo Nordisk A/S and has extensive experience with leadership programmes and global careers discussions. Prior to Medical Affairs, Teresa gained experience in Marketing, Brand management and Corporate Affairs across Denmark and Australia. She obtained her academic degrees in Germany, Chile, Denmark and Spain with the most recent degree being a CEMS Master in International Management.
Brindan Suresh is a Partner with McKinsey and Company based in London. He leads the pharmaceutical practice in the UK & Ireland and co-leads the Firm’s work in Medical Affairs globally. He works primarily with innovator pharmaceutical and medical-device companies in Asia, Europe, and the United States. Brindan focuses on strategy and organizational issues across R&D, Medical and Commercial. He works on a range of topics, helping organizations take a more “science forward, patient back” perspective. This includes recent work helping to set the long-range strategies of a number of clients, the application of digital and analytics across the pharmaceutical value chain, and applying our latest thinking on maximizing talent and leadership across the industry. Brindan convenes our cross-industry medical-affairs leader roundtable and regularly presents our insights externally on innovation-related topics. He also worked as a physician before joining McKinsey, and holds an MD and JD.
Director, Global Medical, Oncology Business Unit/ AstraZeneca
Accountable for medical evidence delivery within Immuno-Oncology and Hematology portfolios at AstraZeneca Pharmaceuticals. She possesses broad evidence generation capabilities and subject matter expertise in early access, real world evidence and external scientific research. Key competences in stakeholder relations and external collaborations, across multi compound oncology research projects in small and large molecules. Broad knowledge and expertise across pharmaceutical, academic and public/private partnerships.
She is a certified Project Management Professional, Oncology Nurse; receiving her MBA from St. Joseph’s University in Philadelphia PA.
Dr. Bernard Hamelin, MD, MSc, MBA, is the Global Head of Medical Evidence Generation within the Medical Function at Sanofi, a global healthcare leader that discovers, develops and distributes therapeutic solutions for patients. In that role, he is responsible for delivering evidence required to demonstrate the value of Sanofi products, from early to late phase development. He also helps driving innovative and collaborative activities in order to engage with the changing healthcare landscape and to improve patient outcomes.
Dr. Hamelin is a Medical Doctor trained in Liver diseases and Gastroenterology in Paris from 1984 to 1991. Bernard joined AstraZeneca in 1991 as responsible for GI clinical and medical affairs programs in the French Affiliate. From 1994 to 2001 Bernard occupied different clinical research roles based in Sweden (Goteborg) and in the USA (Philadelphia). He was the lead physician on the esomeprazole (Proton Pump Inhibitor) project and led the emerging GI global product team. In 2001, Bernard was appointed head of the French AstraZeneca affiliate Medical Affairs team, based in Rueil-Malmaison. His team supported the successful launch of different products (incl. Crestor (statin), Symbicort (inhaled glucocorticosteroid), Arimidex (aromatase inhibitor).
Shauna brings more than a decade of extensive experience across the pharmaceutical, biotech, medical device and research markets. She has a passion for innovation and driving impact and has demonstrated that success through her strong collaborations and supportive partnerships across the healthcare continuum. As the Senior VP of Strategic Accounts at MedEvoke, Shauna is a driven leader providing strategic support and best practices to the organization’s partners and clients. Using her extensive experience and knowledge of the market, clinical development and launch excellence, Shauna employs creative thinking, combined with data insight to deliver unique and strategic solutions. Shauna received her bachelor of science in biology from Salisbury University, in Maryland, with a focus on premed studies and genetic research. She also holds a second bachelor’s degree in psychology from Towson University and earned her MBA degree with a specialization in management and marketing.
Malcolm is Managing Director, of PharmaMedic Consultancy Ltd a London based International biosciences consultancy company, and Immediate Past President of the Section of Pharmaceutical Medicine and Research of The Royal Society of Medicine, London, UK.
With over 20 years experience as a Consultant Pharmaceutical Physician to Industry and Government, Malcolm advises bioscience and pharmaceutical companies on Product Development, Regulatory Strategy and Medical Affairs, focusing on Start-Ups and SMEs. He acts as a Clinical Specialist and Chair to the European Commission’s Biomedical Research Programme (Horizon 2020), lectures in both Europe and the United States on medicinal development, and teaches on the Pharmaceutical Medicine and Regulatory MSc Course of Copenhagen University.
Following a first degree in Physiology at King’s College London, Malcolm qualified in medicine from St Bartholomew’s Hospital, in 1993. After postgraduate training in General and Intensive Care Medicine he joined the UK Government as a Medical Assessor in new medicines in 1997. After senior industry roles at Pfizer and AstraZeneca he re-joined Government as Lead Medical Assessor to the UK Dept of Health’s Clinical Trials Unit on it’s formation in 2005, and worked with the European Medicines Agency (EMA) on the development of a trans-European clinical development process in the pharma and biotech sectors. Leaving full time employment with the Government in February 2007, Malcolm was appointed as an Independent Consultant to the Dept of Health.
He has worked extensively in senior UK and Global consultancy positions with most of the top ten pharma companies including AstraZeneca, Eisai, Roche, Novartis, Schering-Plough / MSD and GSK, in addition to having advisory development roles in the biotech, device and generic pharma sectors.
In 2012 he was appointed President to the Section of Pharmaceutical Medicine and Research at the Royal Society of Medicine, London and in 2014, a Fellow of The Royal Society of Biology.
Helen Kane is the CEO of PIVOT MSL, a specialist training consultancy with a core focus on driving excellence throughout the global MSL community. A pharmacist by background she spent more than two decades working in medical affairs across the life science industry. With a strong track record in the development, management and leadership of MSL teams she was a founding member of the UK professional association for MSLs, and served as Chair 2012-15. Through her many activities she has acquired a reputation and profile as the leading, independent driving force behind the concept of MSL excellence. Respected as a trainer, facilitator, mentor, speaker and expert contributor, Helen believes that ‘it is indeed a beautiful thing when a passion and a career come together.’PIVOT MSL was established as a training consultancy from a belief in the value and impact of the MSL, and a desire to support the wider medical affairs community. Helen is proud to work with a team of selected industry experts who are connected by their desire to transform both individuals and teams. Distinguished by its expertise and a portfolio of innovative training programs for both MSLs and their leaders, PIVOT MSL is regarded as a trusted, go-to resource by clients throughout the world.
Dr. Maru is an academic physician, Neuroimmunologist and health economist with extensive global experience in clinical research and development, translational medicine, health economics, real-world evidence, and medical affairs.
With a specialty in economic modeling and real-world evidence generation, Benit’s scientific and industry career has primarily focused around neurology, neuroimmunology, immuno/haemato- oncology, and biological therapies for inflammatory diseases, nephrology, dermatology and rheumatology, and rare/ultra-rare disease.
Today healthcare asks for technology to transform care management as well makes the ecosystem more sustainable
My goal is to apply resilience and innovation mindset in discovering either a small minimal viable product that improves UX or a transformational solution that can change patient’s life.
I leverage in that my experience of Production & Planning, Project Management, Supply Chain, Strategic Marketing, Sales, Management Consulting and more recently Digital & StartUp, in the Pharmaceuticals and FMCG sectors, at Italian and European level, always serving as people manager but more importantly as a company intrapreneur.
Anna Walz is a 25-year veteran in the pharmaceutical industry and is the CEO of MedEvoke which she founded in 1999. MedEvoke is dedicated to working with Medical Affairs leaders to drive alignment through development of clear medical strategies that can be globally communicated, measured, and analyzed. This has, for the first time, enabled Medial Affairs to track the impact of internal efforts on the external scientific and digital exchanges. Anna, who often speaks on the topics of metrics for medical affairs, female entrepreneurship, and diversity in the biosciences, is also a regular guest-lecturer on the topic of Pharmacology & Drug Marketing at the Rutgers Medical School. In addition to speaking, Anna has a keen interest in her own continuing education and is a graduate of both the Tuck-WBENC Executive Education program and the Entrepreneurial Master’s Program (EMP), a joint collaboration of the Entrepreneurs’ Organization and MIT. She is also actively involved in her community, serving as a Chairman of the Board of Trustees for Hunterdon Regional Community Health, the Hunterdon Healthcare System, and is an active member the Hunterdon Medical Center Strategic Planning Committee. Outside of her professional achievements, Anna earned her black belt in Shito Ru karate, is multiple marathon runner, and enjoys weightlifting at her local crossfit gym.
David qualified in medicine 29 years ago and has extensive experience of primary and secondary care in the UK and Australia, as well as over 19 years as a pharmaceutical physician. Having launched numerous drugs in the UK and Europe, lead HTA submissions and has a wide therapeutic experience, deep real world evidence knowledge and experience.
Previous roles have also included major change agent and medical leader; head of HEOR for UK Global R&D, Global Head of Government Affairs in AZ and Global lead for RWE in general medicine and consumer health Sanofi.
David has extensive knowledge in strategic medical affairs and is a proven change agent both in terms of organization, as well as creatively applying medical understanding. Always advocating for the medical function in all his roles and recognizing the need for medical affairs to be a strong strategic partner. Working now in the technology sector, David is applying practical solutions to complex data solutions.
General Manager UK & Ireland/ Portola Pharmaceuticals
Dr Robert (“Bobby”) Mulrooney is the General Manager for UK & Ireland at Portola Pharmaceuticals a global biotechnology company charting a new course in the treatment of serious blood-related disorders and currently in start-up mode across Europe.
Before Portola he founded Ardiem LifeSciences a boutique consultancy working in partnership with leaders in the biotech, pharma and LifeSciences sector to develop commercial strategy and operational plans which translate strategy to results.
Previously Bobby was Regional General Manager for Jazz Pharma and for 11 years was a Commercial VP at GSK where he held a range of Commercial leadership roles across a broad spectrum of therapy areas and medicines. At GSK, he led the successful launch of a number of biologic and small molecules with an emphasis on rare and orphan disorders.
Prior to GSK, Bobby worked as a Director of Medical Affairs at Bristol-Myers Squibb UK and as Global Development lead for Phase II/III assets in development for Stroke and Traumatic Brain Injury at GlaxoWellcome.
Bobby trained in Medicine in the Republic of Ireland and the UK and worked in Internal Medicine and Cardiology in London; he is a Member of the Royal College of Physicians in Ireland, a Fellow of the Faculty of Pharmaceutical Medicine and a Fellow of the Royal College of Physicians in London.
Tony has over 30 years of experience creating and delivering analytical products and services. In his prior career in the U.S. intelligence community, he directed intelligence operations in various strategic analysis organizations in the US and abroad. Subsequently, Tony used his insight to apply intelligence methodologies to pharmaceutical industry problems. Over the past decade, he has developed the leading-edge technologies that are now Voxx Analytics, creating easy-use advanced analytics for engagement-related challenges. Tony has an MS from National Intelligence University and an MBA from the Peter F. Drucker School of Business.
Sameer heads a business unit at Indegene focusing on services to Medical Affairs organizations in life sciences companies. Sameer drives the overall P&L through sales and marketing efforts, capability building, innovation and delivery. He is also setting up a new service line (value proposition, capability mix, resourcing, external partnership, key client wins) to increase market penetration and drive business growth. He is also the global client partner for several of the top accounts at Indegene. He is responsible for managing a team of professionals based in multiple geographies with a mandate to grow Indegene’s business across service lines.
Sameer has over twenty two years of experience both in the pharmaceutical industry as well as on the services side. Prior to joining Indegene, Sameer has served a variety of leadership roles in companies like GlaxoSmithKline and Sudler & Hennessey. His expertise lies in building long-term strategic client relationships; developing programs to address specific business problems; and effectively executing against set objectives.
Sameer is an MBA in Marketing with a Bachelor’s degree in Chemical Technology
Head of Value Demonstration & Real- World Evidence/ Visformatics
Simon is an experienced health economist, with years of involvement aggregating and interrogating epidemiological, economic, and social media data; Simon is experienced in both identifying and filling evidence gaps critical to supporting core value narratives. In doing so he has published numerous high-impact scientific research papers, in areas including Women’s and children’s health, diabetes, oncology, mental health, mobile-health, emergency medicine and cerebral palsy; all with a primary focus on innovative means of improving patient outcomes.Simon has extensive knowledge of comparative data analytics, market segmentation and social media analysis, using the latter to align internal and externally driven narratives and provide competitive intelligence with respect to market competitors.Simon is a content reviewer for the National Institute for Health Research and the Centre for Disease Control and Prevention, in addition to acting as a mentor within the NHS clinical entrepreneurs program and advising in trial design for two clinical trials units in England. Simon also heads the research department at ORCHA, NHS England’s approved health-app regulator.
Tarun has over 27 years of experience and has been associated with Indegene for the past 17+ years. He leads the technology domain at Indegene and his responsibilities include development of technology-based solutions focused on the healthcare industry. His strengths lie in his technological expertise and business acumen, which help in developing various platforms and next-generation IT solutions.
Gavin is a healthcare communications leader with over twenty years experience, many of which have been centered on patient engagement. In his current role, developing solutions across the OPEN Health Group, he regularly engages with patient advocates to develop compliant and effective partnerships with the joint aim of improving patient outcomes. His specialist areas of interest are rare disease, patient engagement, pathway improvement and long term outcomes follow up.
Richard White is the Chief Operating Officer of Oxford PharmaGenesis, a global, independent HealthScience communications consultancy. He has more than 20 years of experience in Medical Affairs, and founded the Oxford PharmaGenesis Value Demonstration and Patient Engagement Practices to apply evidence-based communication best practice to clinical, HEOR, RWE, patient-reported outcome (PRO) and patient preference studies. He has run training workshops in these areas for multiple pharmaceutical companies, and has also delivered invited presentations, panel discussions and roundtables at international conferences such as ISMPP, TIPPA, Patient Summit Europe, Patient Engagement & Experience Summit and the World Orphan Drug Congress. Richard was Chair of the 2017 and 2018 TIPPA Annual Meetings, and was Chair of the 2019 EMWA Annual Symposium on RWE.
Richard is a member of MAPS, ISMPP, ISPOR, EMWA, AMCP, and the Institute of Directors. He has authored more than 20 peer-reviewed publications and white papers on value demonstration, good publication practice, and patient engagement in Pharma Times, Pharmaceutical Market Europe, the Journal of Comparative Effectiveness Research and Medical Writing.
Before joining Oxford PharmaGenesis, Richard gained his MA and PhD in Natural Sciences from the University of Cambridge, UK. His PhD research won the 1998 Glaxo Wellcome Young Investigator’s Award, and he was awarded a Research Fellowship in Pharmacology at Sidney Sussex College, Cambridge, UK. He has completed the Advanced Health Economic Modelling Program at the University of Oxford, UK, and is an alumnus of the International Marketing Program at INSEAD, France. Richard is currently a member and College Adviser at Green Templeton College, University of Oxford.
Strategy consultant in Life Sciences for 14 years, Casper has extensive experience in defining and implementing transformational strategies in Medical Affairs, Market Access, Commercial and Value-based Healthcare. He is the sponsor of the Medical Affairs Centre of Excellence in Vintura. Casper is a strong believer in co-creation and collaboration with multiple healthcare stakeholders to reach the best outcomes for patients.
Experienced in end-to-end medical affairs delivery specializing in designing and delivering bespoke strategic real-world evidence generating plans for his clients. Developed a specialist interest in the design and implementation of rare disease registries. More than 15 years of experience in pharmaceutical medicine, medical law and ethics and business theory and founded Medialis to leverage this unique blend of all three disciplines. A strong advocate for Medical affairs as the key to successfully commercializing a medicine without it, or the influence it can bring, a medicine’s true value will never be realized.
Lead Facilitator and Executive Coach/ Amplity Health
Fiona is curious about people and about business. She is Passionate about helping people connect with their spirit in both a professional and personal context – inspiring the leader within to shine. Fiona has been part of Amplity Health since the company’s inception and has been an integral member of the team ever since. Prior to that she had a successful career in the pharmaceutical industry with over 15 years working in a variety of sales, management, training, coaching and Organisational Development roles.
Fiona has experience across the whole Amplity Health portfolio and has developed or been instrumental in the design of many programmes.
Consistent feedback from clients is that Fiona understands the dynamics and the politics of senior executive teams and is able to navigate a path of empathy and challenge. She manages to hold the space for people to express what the real issues are and ensure that people learn and grow. By recognising and appreciating the capability of individuals and teams, Fiona will choose the appropriate intervention, whether that be informing, confronting or catalytic.
Fiona works closely with clients across the full spectrum of the pharmaceutical industry across a range of different disease areas in both pre and post licence phases. She understands why good governance is important from a strategic perspective and helps people find what they need so they can operate with confidence and credibility when interacting with stakeholders.
As well as being an accredited MBTI Facilitator and an accredited Change Management Facilitator, Fiona is a qualified NLP Practitioner and a certified Performance Coach (Newcastle University). She is also a Senior Yoga Teacher (RYT 500 Yoga Alliance) and studied Mindfulness at Oxford. It is because of this breadth of skills and experience that Fiona is able to be versatile and flexible when working with individuals and groups.
Catriona Scott is a Scientific Strategy Advisor at Oxford PharmaGenesis, Oxford, UK, a global, independent HealthScience communications consultancy. She has managed strategic projects within the pharmaceutical industry at all levels, leading analysis, redesign and implementation with cross-functional teams, and has led creation and implementation of scientific communications platforms. Catriona has more than 16 years of experience in all aspects of medical communications and publications, across all stages from preclinical to post-marketing and for all audiences. She gained her medical degree from the University of Edinburgh, UK.
Europe Lead – Medical Affairs Practice Area/ ZS Associates
Bora is leading ZS’ Medical Affairs practice area in Europe. He has helped biopharmaceutical companies develop and implement medical affairs strategy through effective execution by field based medical teams. He has led programs to define, collect and communicate the Medical Affairs value story for number of his clients. During his career, he has been working within various therapeutic areas such as cardiovascular, diabetes, oncology and respiratory disorders. He holds a PhD degree in Biophysics from Johns Hopkins University School of Medicine.
Alex is a Global Business Ethics Director at Ipsen with 14 years Pharmaceutical experience. He currently supports the Global Medical Affairs team at Ipsen as well as the Neurosciences and Rare Disease Global teams. He is passionate about promoting ethical decision making, bringing clarity to complicated regulations and simplifying processes. He has a degree in Biological Sciences from Lancaster University and has worked in manufacturing, clinical development and commercial areas. Among many international projects, he led the HCP/ HCO payment transparency implementation across Europe for a multi-national Japanese company. He has also led Fair Market Value implementation internationally (ex-US) at a medium-sized American company. Before joining Ipsen he was the UK & Ireland compliance officer at AbbVie.”
Global Lead – Medical Affairs Practice Area/ ZS Associates
Sarah Jarvis leads the medical affairs consulting space at ZS. Sarah has worked in the healthcare space for more than 20 years. She currently helps medical affairs clients bring business- and customer-oriented solutions to teams as varied as medical science liaison teams, medical information teams, medical communications teams and others groups within the medical affairs departments across both small and large pharmaceutical and biotech companies. Sarah has worked extensively with pre-launch products, from phase 1 to phase 3 through to pre-launch, as well as with in-market products in the U.S. and Europe across multiple disease states, including oncology and immunology.